Sekundärprävention nach Myokardinfarkt

Autor: J.E. Pflumm, T. Pomykaj, M.P. Heintzen

Publikováno v: Der Internist. 49:1052-1060

Die Sterblichkeit nach akutem Myokardinfarkt hat sich in den letzten Jahren signifikant verringert. Fur die verbesserte Prognose in der Fruhphase nach Myokardinfarkt sind v. a. die weiterentwickelten pharmakologischen und interventionellen Revaskular

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37768911040023712f94eeefbe21104d
https://doi.org/10.1007/s00108-008-2077-0

Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial

Autor: Eliot A. Brinton, Uma Kher, Sukrut Shah, Christopher P. Cannon, Michael Davidson, Antonio M. Gotto, Tanya B. Ashraf, Christine McCrary Sisk, Hayes Dansky, Yale Mitchel, Philip Barter, M. Gerstman, L. Howes, K. Kostner, P. Nestel, D. Sullivan, H. Brath, J. Patsch, B. Paulweber, H. Toplak, C.M. Constance, E. Howlett, D. Mymin, L. Pliamm, K.K. Saunders, J.-C. Tardif, R. Tytus, P. Aschner, S. Keinänen-Klukaanniemi, T. Strandberg, M.-R. Taskinen, G. Luc, D. Richter, J.L. Schlienger, Y. Zaïr, K.-F. Appel, M. Baar, C. Luley, U. Overhoff, T. Pomykaj, T. Schaefer, S.T. Lau, K.L.F. Lee, K. Tan, B. Tomlinson, M.W. Tsang, K. Badacsonyi, Á. Kalina, N. Kanakaridisz, L. Márk, É. Péterfai, L. Regos, I. Reiber, J. Takács, A. Vértes, A. Elis, D. Gavish, D. Harats, O. Hussein, T. Hayek, E. Leitersdorf, A.K. Bin Abdul Ghapar, K.H. Chee, S.B. Ismail, K.H. Ling, G.R.L. Ramanathan, K.H. Sim, R. Alvarado, M. Benavides, G.E. Cardona, G. Gonzalez, J. Verdejo, D.C.G. Basart, B.P.M. Imholz, J.J.C. Jonker, P.R. Nierop, J.L. Posma, Th.B. Twickler, E. Barrington-Ward, R. Cutfield, D.H. Friedlander, R.S. Scott, H. Istad, G. Langslet, G.K. Skjelvan, S.J. Campodónico Hoyos, R. Coloma Araniya, A. Gallegos C., C.A. Pino Morales, L. Watanabe, G.P. Arutyunov, A.B. Blokhin, M.G. Bubnova, S.Y. Marcevich, C. Álvarez Sánchez, L.A. Álvarez-Sala Walther, B. Gil Extremera, F. Perez Jimenez, L. de Teresa Parreño, C.-P. Anderberg, U. Hedin, A. Hellberg, P. Höök, T. Kjellström, P. Nilsson, A.G. Olsson, U. Rosenqvist, K. Tolagen, T. Wolff, A. Baskin, H.E. Bays, R.I. Bernstein, N. Bittar, E.A. Brinton, L.H.K. Chee, R.A. Cottiero, R.D. D'Agostino, M.H. Davidson, P.S. Denker, R.K. Garcia, R.K. Hippert, T. Isakov, S.R. Kaster, B. Kerzner, E.J. Klein, M.J. Koren, M.E. Kutner, D. Liljenquist, D.G. Lorch, R. Lorraine, B.C. Lubin, N.M. Lunde, T.J. Majchrzak, J.M. McKenney, S. Mukherjee, D.D. Muse, M.S. Otruba, J.E. Pappas, K. Patrick, S.J. Powell, E. Riffer, L.D. Rink, J.L. Rohlf, J.B. Rosen, P.D. Rosenbilt, E.M. Roth, C.J. Rubenstein, J. Rubino, L.A. Rudolph, A. Schneider, W.G. Short, J.C. Silverfield, D.P. Suresh, G.A. Tarshis, P.D. Toth, R.W. Townsend, T.O. Wahl

Publikováno v: Journal of clinical lipidology

Background In the Determining the Efficacy and Tolerability of cholesteryl ester transfer protein (CETP) INhibition with AnacEtrapib (DEFINE) trial, anacetrapib added to statin produced robust low-density lipoprotein cholesterol (LDL-C)-lowering and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0c778769d9b9d7a78e7c69d7f43bd3
https://pubmed.ncbi.nlm.nih.gov/25670362

Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study

Autor: J P D, Reckless, P, Henry, T, Pomykaj, S T, Lim, R, Massaad, K, Vandormael, A O, Johnson-Levonas, K, Lis, P, Brudi, C, Allen

Publikováno v: International journal of clinical practice. 62(4)

The aim of this study was to investigate the efficacy and safety profile of switching to ezetimibe/simvastatin (Eze/Simva) 10/40 mg compared with doubling the statin dose upon discharge in patients taking a statin and admitted to the hospital for the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cf2b1b474690c04780800bb7e1150457
https://pubmed.ncbi.nlm.nih.gov/18324945

[Nocturnal ventricular arrhythmia in patients with sleep apnea and suspected coronary heart disease]

Autor: U, Koehler, T, Glaremin, W, Cassel, M, Feuring, T, Pomykaj, H, Schäfer, M, Stellwaag

Publikováno v: Medizinische Klinik (Munich, Germany : 1983). 88(12)

Patients with sleep apnea and nocturnal brady- and tachyarrhythmia are considered to be patients at especially high risk within the group of all apnea patients.13 patients with sleep apnea (apnea-index10 events/h), suspected coronary heart disease an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0b76296f9e682f3f804a4cf56273c146
https://pubmed.ncbi.nlm.nih.gov/7510360

Nocturnal myocardial ischemia and cardiac arrhythmia in patients with sleep apnea with and without coronary heart disease

Autor: T. Pomykaj, H. Junkermann, H. Dübler, P. von Wichert, J. H. Peter, Ulrich Koehler, Thomas Ploch, T. Glaremin, Lübbers C

Publikováno v: Klinische Wochenschrift. 69(11)

To study the effect of apnea and hypoventilation-induced hypoxemia on the heart, we carried out polysomnographic recordings over; 4 nights with electrocardiographic tracings in 30 patients with and without coronary heart disease. Evaluations of the d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4788b13174b9df38293206572c0f513
https://pubmed.ncbi.nlm.nih.gov/1921230